重组人血小板生成素联合激素治疗血小板减少性紫癜效果评价.docVIP

重组人血小板生成素联合激素治疗血小板减少性紫癜效果评价 　　[摘要]目的 探究重组人血小板生成素联合激素治疗血小板减少性紫癜（ITP）的临床效果。方法 选取2015年3月～2017年6月我院收治的60例ITP患者为研究对象，采用随机数字表法分为观察组和对照组各30例。对照组采用糖皮质激素治疗，观察组则在对照组基础上加用重组人血小板生成素治疗，比较两组患者治疗前后的血小板计数、血小板回升时间。结果 观察组患者治疗总有效率为83.3%（25/30），显著高于对照组的66.7%（20/30），差异有统计学意义（P0.05）；观察组患者治疗后的血小板计数改善显著高于对照组，且血小板上升时间显著短于对照组，差异有统计学意义（P0.05）。结论 重组人血小板生成素联合激素治疗ITP的效果确切，能够快速促进血小板的生成，值得在临床上推广和应用。 　　[关键词]血小板减少性紫癜；重组人血小板生成素；糖皮质激素；疗效 　　[中图分类号] R554.6 [文献标识码] A [文章编号] 1674-4721（2017）11（b）-0023-03 　　[Abstract]Objective To investigate the clinical efficacy of Recombinant Human Thrombopoietin combined with Hormone in the treatment of thrombocytopenic purpura（ITP）.Methods 60 patients with ITP who treated in our hospital from March 2015 to June 2017 were selected as subject，they were randomly divided into observation group and control group，with 30 cases in each group.The control group was treated with Glucocorticoid therapy，and the observation group was used Recombinant Human Thrombopoietin treatment based on the control group，and platelet count，platelet recovery time were compared between the two groups before and after treatment.Results The total efficiency of the observation group was 83.3%（25/30），significantly higher than the control group 66.7%（20/30），the difference was statistically significant （P0.05）； patients in the observation group after treatment improved the platelet count was significantly higher than the control group， and platelet rise time significantly lower than the control group，the difference was statistically significant （P0.05）.Conclusion Recombinant Human Thrombopoietin combined with Hormone therapy is effective in the treatment of ITP，which can promote the production of platelets rapidly and deserve clinical application and promotion. 　　[Key words]Thrombocytopenic purpura；Recombinant Human Thrombopoietin；GLucocorticoid；Curative effect 　　血小板减少性紫癜（ITP）是一类常见的出血性疾病，多见于儿童及中青年，患者主要表现为不同程度的凝血功能障碍[1]。该病的传统治疗方案主要为糖皮质激素治疗，但部分患者的疗效较差[2-3]。近年来的研究发现血小板生成素在促进巨核细胞分化和血小板生成中有着重要的作用[4]，而随